ALDR: Alder Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company.

Company Shares of Alder BioPharmaceuticals, Inc. Rally 8.54%

By David Cooper -

 

Jun 7, 2015

 

52

 

0

Shares of Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) rose by 8.54% in the past week and 23.96% for the last 4 weeks. In the past week, the counter has outperformed the S&P 500 by 9.29% and the outperformance increases to 25.34% for the last 4 weeks.

The company shares have rallied 197.74% from its one year high price. On June 5, 2015 The shares registered one year high of $47.93 and one year low was seen on October 13, 2014 at $10.52. The 50-day moving average is $34.01 and the 200 day moving avarge is recorded at $27.92. S&P 500 has rallied 7.25% during the last 52-weeks. 27.12% of the shares are held by the company Insiders, 7.8% of the shares are held by the institutions. Company shares has an average 3 month share volume of 471,692 and an average 10 day volume is recorded to be 1,023,150

Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) : On Friday heightened volatility was witnessed in Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) which led to swings in the share price. The shares opened for trading at $47.36 and hit $47.93 on the upside , eventually ending the session at $46.15, with a gain of 0.57% or 0.26 points. The heightened volatility saw the trading volume jump to 2,729,917 shares. The 52-week high of the share price is $47.93 and the company has a market cap of $1,752 million. The 52-week low of the share price is at $10.52 .

Alder Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops and seeks to commercialize therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. The Companys pipeline include two internally discovered humanized monoclonal antibodies, one wholly owned program and one partnered program, as well as preclinical programs targeting additional indications that are in the discovery phase. The Companys antibody platform leverages three technologies for the selection, humanization and manufacturing of monoclonal antibodies. ALD403 is its wholly owned monoclonal antibody targeted to calcitonin gene-related peptide (CGRP), for migraine prevention. Clazakizumab is a monoclonal antibody that inhibits the pro-inflammatory cytokine interleukin-6, or IL-6, and is being developed for both rheumatoid arthritis (RA), and psoriatic arthritis (PsA).